Work

Desmoda: The latest US FDA-approved oral desmopressin solution for all age groups

Year: 2026

Type: article

Abstract: Central diabetes insipidus (CDI) is an uncommon condition characterized by deficient vasopressin secretion, resulting in polyuria, polydipsia, and the potential for dehydration and electrolyte disturbances. Desmopressin, a synthetic form of vasopressin, remains the cornerstone of treatment. Desmoda, an oral liquid formulation of desmopressin approved by the United States Food and Drug Administration, provides a novel, ready-to-use option appropriate for all age demographics, especially infants and individuals with dysphagia. It facilitates accurate, weight-based dosing without requiring tablet handling or refrigeration. Desmoda signifies significant progress in CDI care; however, caution is warranted regarding hyponatremia and its use in patients with renal impairment.

Source: Saudi Journal of Anaesthesia

DOI: 10.4103/sja.sja_509_26

Authors: Konica Chittoria, Ankur Sharma, Arun Mukesh, Varuna Vyas

Institutions: All India Institute of Medical Sciences Rishikesh, All India Institute of Medical Sciences Jodhpur, Jawaharlal Institute of Post Graduate Medical Education and Research

Language: English

Topic: Electrolyte and hormonal disorders

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7215066691

FWCI:

Cites: 12

Cited by:

Related to: 10